Guosen Securities: Consumer healthcare sector poised for value re-rating amid valuation divergence; seek undervalued high-quality stocks within the segment

As operating metrics gradually improve, industry consolidation advances, and the development trajectory of mature markets is validated domestically, the consumer healthcare sector is poised to transition from valuation divergence to value reassessment.

Zhitong FinanceAug 14 09:15

Repurchase announcements disclosed in a concentrated manner reveal the latest portfolio adjustments by a group of star fund managers.

① Since July, publicly offered funds have shown divergent positioning adjustments in hard-tech stocks such as semiconductors and electronic chemicals; ② Yang Zongchang, who successfully 'timed the market peak,' has newly entered the top ten circulating shareholders of Sany Heavy Industry through his fund products; ③ Some fund managers have reduced holdings in upstream mining and smelting and midstream manufacturing segments of the new energy sector, while newly entering the top ten circulating shareholders of power grid equipment companies; ④ According to current disclosures, prominent fund managers including Ge Lan, Zhang Kun, and Huang Xingliang have all reduced their positions in pharmaceutical stocks.

cls.cnAug 9 16:04

Yifeng Pharmacy (603939.SH): Repurchased 1.7756 million shares of the company's stock for the first time

Gelonghui, August 6 — Yifeng Pharmacy (SHA: 603939) announced that on August 6, 2026, the company repurchased 1.7756 million shares for the first time through the centralized bidding trading system of the Shanghai Stock Exchange, representing 0.15% of the company's total share capital. The highest repurchase price was RMB 22.62 per share, and the lowest was RMB 22.01 per share, with a total amount paid of RMB 39.6195 million (excluding stamp duty, brokerage commissions, and other transaction fees).

Gelonghui FinanceAug 6 15:45

Nomura Adjusts Yifeng Pharmacy Chain's Price Target to 33.97 Yuan From 35.50 Yuan, Keeps at Buy

MT NewswiresAug 3 16:12 · Ratings

Yifeng Pharmacy (603939.SH): Has not yet repurchased any of its shares.

Gelonghui, August 3 — Yifeng Pharmacy (SHA: 603939) announced that, as of July 31, 2026, the company has not yet repurchased any of its shares through a repurchase-dedicated account via centralized bidding.

Gelonghui FinanceAug 3 15:47

Increased Buybacks and Repurchases: Industrial Capital from Shanghai-Listed Companies Continues to Enter the Market at Full Speed

① Over the past week, 42 new share repurchase plans were announced on the Shanghai Stock Exchange, with a combined upper limit of RMB 8.386 billion; 17 new share purchase (by controlling shareholders or insiders) plans were announced, with a combined upper limit of RMB 7.457 billion. ② Industrial capital has maintained a consistently high pace of market entry this year. Since the beginning of 2026, the Shanghai Stock Exchange has seen 190 newly disclosed share repurchase plans, amounting to a total upper limit of RMB 55.5 billion, and 155 newly disclosed share purchase plans with a total upper limit of RMB 22.1 billion.

cls.cnJul 26 16:57